1-5 of 5
Pascal Deschatelets, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

Raymond S Wong, MBChB, MD, Kalina Ignatova, Humphrey Pullon, Jameela Sathar, Pimjai Niparuck, MD, Tontanai Numbenjapon, Eric Tse, MBBS, PhD FRCP, FRCPath, Surapol Issaragrisil, MD, Eloy Roman, MD, Ismail Amine, Lisa Tan, Carl Di Casoli, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Andrija Bogdanovic
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134436
Published: 2020
Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-142174
Published: 2020
Journal Articles

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA)

Federico Grossi, MD, Merrill Kingman Shum, MD, Morie A. Gertz, MD, Eloy Roman, MD, Pascal Deschatelets, PhD, Mohamed Hamdani, MS, Frank Stout, Cedric G Francois, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3623.
https://doi.org/10.1182/blood-2018-99-119468
Published: 2018
Journal Articles

Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Raymond SM Wong, MRCP, FRCP, Humphrey W.H. Pullon, FRACP, FRCPA, Pascal Deschatelets, PhD, Cedric G Francois, MD PhD, Mohamed Hamdani, MS, Surapol Issaragrisil, MD, Patrick Johnson, PhD, Pimjai Niparuck, MD, Tontanai Numbenjapon, MD, Jameela Sathar, MB, MRCP, MRCPath, Lisa Tan, Eric Tse, MBBS, PhD FRCP, FRCPath, Federico Grossi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2314.
https://doi.org/10.1182/blood-2018-99-110827
Published: 2018
Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD
Journal: Blood
Blood (2016) 128 (22): 1251.
https://doi.org/10.1182/blood.V128.22.1251.1251
Published: 2016